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Introduction {#sec005}
============

Breast cancer remains the most prevalent and incident cancer in most countries. The World Health Organization estimated 2.1 million new cases of female breast cancer in 2018 \[[@pone.0237811.ref001]\]. The triple-negative breast cancer (TNBC) subtype, which is negative for the progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor 2 receptor expression (HER2), accounts for approximately 10% of all the breast cancers \[[@pone.0237811.ref002]\]. However, a previous study identified a prevalence of 21.3% in a single Peruvian center \[[@pone.0237811.ref003]\].

The TNBC subtype is more aggressive and has worse survival outcomes compared to non-TNBC \[[@pone.0237811.ref004]\]. Patients with TNBC are more likely to be younger, obese, have a family history of breast cancer and non-Hispanic black women \[[@pone.0237811.ref005]--[@pone.0237811.ref007]\]. Moreover, Latin American population have a greater percentage of TNBC diagnosis, as well as HER2+ \[[@pone.0237811.ref008], [@pone.0237811.ref009]\]. Nevertheless, studies have not established if these demographic characteristics have a real impact on survival prognosis. In contrast, pathologic tumor features (large tumor size, lymph node involvement, and advanced stages) have a clear association with worse survival outcomes \[[@pone.0237811.ref010], [@pone.0237811.ref011]\].

Nonetheless, few reports have addressed the long-term survival outcomes of women with TNBC \[[@pone.0237811.ref011]--[@pone.0237811.ref013]\]. Haque *et al*. \[[@pone.0237811.ref012]\] reported an overall survival (OS) of 66% in TNBC patients at 20 years, while Li *et al*. \[[@pone.0237811.ref013]\] described 80% at seven years. Furthermore, Chandra *et al*. \[[@pone.0237811.ref011]\] reported an OS of 75% at eight years with a median follow-up of 42 months.

On the other hand, social environment has been described as having a negative impact on patient survival in Peru and other countries. This is due to insufficient access to health care services and unawareness of diagnostic tests \[[@pone.0237811.ref014]\]. There are scarce data on the clinicopathological features of TNBC in South America. Thus, the purpose of our study was to identify the sociodemographic, clinicopathological and therapeutic characteristics, as well as patient outcomes including long-term event-free survival (EFS) and OS in Peruvian women with TNBC. In addition, we report disease recurrence and prognostic factors of mortality at 10 years.

Materials and methods {#sec006}
=====================

Patients and design {#sec007}
-------------------

This was a retrospective cohort study, approved by the institutional review board of the National Institute of Health Disease (INEN, "Instituto Nacional de Enfermedades Neoplásicas"). We included incident TNBC patients treated at the INEN from 2000 to 2014. The medical records were accessed from January 2016 to January 2017 and the follow-up data was updated in February 2020. Cases which were lost to follow-up after surgery were excluded from the study. Patients were treated with surgical or medical therapy. Patients undergoing surgery received breast-conserving surgery (BCS) plus radiotherapy, chemotherapy, or both; and total mastectomy (TM) \[[@pone.0237811.ref015]\] plus chemotherapy or radiotherapy. Medical treatment consisted of chemotherapy. Patients with positive margins underwent a re-excision procedure. Regardless of the treatment (surgical or medical), all cases were included. Some patients did not received chemotherapy for the following reasons: will of the patients or decision for palliative care due to metastatic disease. Patients were identified by immunohistochemical confirmation of TNBC (estrogen-receptor \[ER\] negative or \<1%, progesterone-receptor \[PR\] negative or \<1%, and human epidermal growth factor receptor 2 \[HER2\] negative or \<1%), tumors with a HER2 inconclusive staining intensity were evaluated with fluorescence in situ hybridization (FISH), for confirming the negativity with a result less than 2. In regard to molecular and genetic tests as Oncotype and BRCA-1/2, the National Health Insurance do not provide these tests for the population, with an exception of FISH for HER2 expression, which could be done in the case of inconclusive immunohistochemical test. Some patients could be tested in other private institutions; however, those results were not registered. The 8^th^ edition of the American Joint Committee on Cancer (AJCC) was employed to classify the tumor stage of the patients. Moreover, the body mass index (BMI) was classified as underweight (\<18.50 km/mt^2^), normal (18.50--24.99 km/mt^2^), overweight (25.0--29.99 km/mt^2^), obese I (30.0--34.99 km/mt^2^), and obese II (≥35 km/mt^2^). Moreover, we described the region of birth of patients as follows: Lima (capital of Peru), Coast (excluding Lima), Mountains and Jungle.

Follow-up {#sec008}
---------

The study follow-up started at the time of first treatment; therefore, we defined OS until the date of an event (death or end of the study), and EFS until locoregional or distant relapse, progression, death, or end of the study. We ensured a minimum observation of 36 months for the OS unless death occurred first. Breast cancer recurrence was identified by computed tomography or magnetic resonance and a biopsy.

Statistical analysis {#sec009}
--------------------

We used the median and range to report the age and BMI of the patients. Furthermore, the Chi-square test examined the differences between qualitative variables, and the McNewar test was used for quantitative variables. Moreover, the Kaplan-Meier method was used to compute the survival curves, and the Log-rank test estimated the differences between tumor stages. Furthermore, the prognostic factors for disease recurrence and mortality were estimated with multivariate Cox regression analysis and reported with proportional hazard ratios \[[@pone.0237811.ref016]\] and a 95% confidence interval \[[@pone.0237811.ref009]\]. We excluded cases with missing values of the variables menopausal status and histologic grade, which yielded a model adjusted for the following variables: age, breast or ovarian family history, menopausal status, T staging, N staging, histologic grade, chemotherapy and radiotherapy. The results were considered statistically significant with a p value \< 0.05. Both multivariate models were assessed with the command "cox.zph" and assumed the proportional HR assumption. Data were analyzed using the software R 3.5.3 version and the packages "survival" and "survminer".

Ethical aspects {#sec010}
---------------

This study was approved by the Institutional Research Ethics Committee of the "Instituto Nacional de Enfermedades Neoplásicas". We blinded the identity of the participants, replacing their information with unrelated codes (e.g. 1, 2).

Results {#sec011}
=======

Baseline demographic characteristics {#sec012}
------------------------------------

We analyzed a total of 2007 patients diagnosed with TNBC ([Fig 1](#pone.0237811.g001){ref-type="fig"}). [Table 1](#pone.0237811.t001){ref-type="table"} shows the baseline sociodemographic characteristics of the overall population. The median age at diagnosis was 49 years (19--95 years), and most patients were between 40--59 years of age. We found a high prevalence of overweight (34.7%), postmenopausal status (54.6%), and family history of breast or ovarian cancer in a first- or second-degree relative (10.4%). Furthermore, our study showed that hypertension and diabetes mellitus (DM) had a prevalence of 9.9% and 8.1%, respectively. In fact, hypertension was more common in the overweight (8.8%) and obese patients (19.7%). Similar results were obtained for DM, with 8.2% and 14.0% in overweight and obese patients, respectively. Moreover, our patients were more likely to have T2 or T4 T staging, N0-1 N staging, AJCC tumor staging II-III, and histologic grade III ([Table 2](#pone.0237811.t002){ref-type="table"}).

![Graphic schematization of patient inclusion in the study.](pone.0237811.g001){#pone.0237811.g001}

10.1371/journal.pone.0237811.t001

###### Baseline sociodemographic characteristics of the overall population.

![](pone.0237811.t001){#pone.0237811.t001g}

  Characteristics                                         Total population (N = 2,007)   Percentage (%)/range
  ------------------------------------------------------- ------------------------------ ----------------------
  Age (median)                                            49                             19--95
  Age (years)                                                                            
      \<30                                                64                             3.2
      30--39                                              373                            18.6
      40--49                                              602                            30.0
      50--59                                              512                            25.5
      60--69                                              298                            14.8
      ≥70                                                 158                            7.9
  Region of birth                                                                        
      Lima                                                579                            28.85
      Coast (excluding Lima)                              811                            40.41
      Mountains                                           479                            23.87
      Jungle                                              138                            6.87
  Body mass index (median)                                26.84                          14.67--54.42
  Body mass index                                                                        
      Underweight                                         22                             1.1
      Normal                                              553                            27.6
      Overweight                                          696                            34.7
      Obese I                                             335                            16.7
      Obese II                                            93                             4.6
      Obese III                                           23                             1.1
      Missing                                             285                            14.2
  Menopausal status                                                                      
      Premenopause                                        889                            44.3
      Postmenopause                                       1095                           54.6
      Missing                                             23                             1.1
  Family history                                                                         
      Cancer family history                               581                            28.9
      Breast or ovarian cancer in 1^st^ degree relative   117                            5.8
      Breast or ovarian cancer in 2^nd^ degree relative   93                             4.6
      Breast or ovarian cancer in 3^rd^ degree relative   36                             1.8
      Breast or ovarian cancer in ≥2 relatives            58                             2.9
  Reproductive history                                                                   
      Number of children (median)                         2                              0--14
      Number of pregnancies (median)                      3                              0--22
      Patients with history of abortion                   740                            36.9

10.1371/journal.pone.0237811.t002

###### Baseline clinicopathological and therapeutic characteristics of the overall population.

![](pone.0237811.t002){#pone.0237811.t002g}

  Characteristics                      Total population (N = 2,007)   Percentage (%)
  ------------------------------------ ------------------------------ ----------------
  T classification                                                    
      T0                               5                              0.2
      T1                               191                            9.5
      T2                               669                            33.3
      T3                               229                            11.4
      T4                               798                            39.8
      Missing                          115                            5.7
  N classification                                                    
      N0                               651                            32.4
      N1                               715                            35.6
      N2                               302                            15.0
      N3                               200                            10.0
      Missing                          139                            6.9
  Tumor stage                                                         
      Stage I                          144                            7.2
      Stage II                         687                            34.2
      Stage III                        1,024                          51.0
      Stage IV                         131                            6.5
      Missing                          21                             1.0
  Laterality                                                          
      Right                            944                            47.0
      Left                             1,027                          51.2
      Bilateral                        36                             1.8
  Histologic grade                                                    
      Grade I                          18                             0.9
      Grade II                         305                            15.2
      Grade III                        1,378                          68.7
      Missing                          306                            15.2
  Histological Subtype                                                
      Ductal                           1,860                          92.7
      Lobular                          46                             2.3
      Medullar                         32                             1.6
      Metaplastic                      16                             0.8
      Epidermoid                       8                              0.4
      Apocrine                         6                              0.3
      Mucinous                         4                              0.2
      Secretor                         2                              0.1
      Adenoid cystic                   2                              0.1
      Others                           31                             1.5
  Surgery as first line of treatment   1,064                          53.0
  Surgery                              1,515                          75.5
      Conservative                     488                            32.2
      Mastectomy                       1,027                          67.8
      No Surgery                       485                            32.0
  Neoadjuvant Chemotherapy             744                            37.1
  Adjuvant Chemotherapy                987                            49.2
  Radiotherapy                         1,012                          50.4
  Local relapse                                                       
      Yes                              677                            33.7
      No                               1,330                          66.3
  Distant relapse                                                     
      Yes                              1,047                          52.2
      No                               960                            47.8

Surgical and treatment characteristics {#sec013}
--------------------------------------

Among the medical therapies administered, 37.1% of the patients received neoadjuvant chemotherapy, 50.8% received adjuvant chemotherapy and 50.4% adjuvant radiotherapy. Surgery was the first line of treatment in 53% of the population ([Table 2](#pone.0237811.t002){ref-type="table"}). Of the 1515 patients who had surgery (75.5%), most underwent TM (72.5%). Patients undergoing BCS (32.2%) had a higher percentage of positive margins, and therefore a high frequency of re-excision. However, the proportion of positive vascular permeation and perineural invasion was higher in patients with TM ([Table 3](#pone.0237811.t003){ref-type="table"}).

10.1371/journal.pone.0237811.t003

###### Surgical characteristics of the population according to type of surgery.

![](pone.0237811.t003){#pone.0237811.t003g}

  Characteristics       Breast-conserving surgery (%) N = 488   Total mastectomy (%) N = 1,027   P-value
  --------------------- --------------------------------------- -------------------------------- ---------
  Margins status                                                                                 \<0.001
      Negative          317 (64.9)                              944 (91.9)                       
      Positive          137 (28.1)                              36 (3.5)                         
      Missing           34 (7.0)                                47 (4.6)                         
  Re-excision                                                                                    \<0.001
      No                300 (61.5)                              946 (92.1)                       
      Yes               168 (34.4)                              34 (3.3)                         
      Missing           20 (4.1)                                47 (4.6)                         
  Vascular permeation                                                                            0.004
      Negative          182 (37.3)                              438 (42.6)                       
      Positive          129 (26.4)                              457 (44.5)                       
      Missing           177 (36.3)                              132 (12.9)                       
  Perineural invasion                                                                            0.002
      No                220 (45.1)                              641 (62.4)                       
      Yes               47 (9.6)                                238 (23.2)                       
      Missing           221 (45.3)                              148 (14.4)                       

Treatment outcomes and survival analysis {#sec014}
----------------------------------------

The median follow-up was 153 months (12.75 years), and after 10 years of observation, the rate of local recurrence was 31.9%, and 51.4% for distant recurrence. The most frequent sites for breast cancer metastasis were the lungs (14.5%), followed by bone (9.7%), brain (9.6%) and liver (7.9%) ([Fig 2](#pone.0237811.g002){ref-type="fig"}). [Table 4](#pone.0237811.t004){ref-type="table"} shows that the OS of the entire population at three, five, and ten years was 64%, 56%, and 47%, respectively. Moreover, the EFS and OS of patients continually decreased according to AJCC staging at three, five, and ten years ([Table 4](#pone.0237811.t004){ref-type="table"}, [Fig 3A and 3B](#pone.0237811.g003){ref-type="fig"}). The prognostic factors for both mortality and disease recurrence were an older age, higher T or N status, and absence of chemotherapy and radiotherapy ([Table 5](#pone.0237811.t005){ref-type="table"}).

![Frequency of site of metastasis in Peruvian triple-negative breast cancer patients.](pone.0237811.g002){#pone.0237811.g002}

![(A) Overall survival according to AJCC Staging. (B) Event-free survival according to AJCC Staging.](pone.0237811.g003){#pone.0237811.g003}

10.1371/journal.pone.0237811.t004

###### Overall survival and event-free survival probabilities of patients with tumor stage I-IV.

![](pone.0237811.t004){#pone.0237811.t004g}

  Survival outcomes      Time periods   P-value        
  ---------------------- -------------- --------- ---- -----------
  Event-free survival                                  \<0.00001
      Total population   55             49        41   
      Stage I            89             83        68   
      Stage II           82             73        65   
      Stage III          40             34        28   
      Stage IV           1              0         0    
  Overall survival                                     
      Total population   64             56        47   
      Stage I            97             92        76   \<0.00001
      Stage II           90             82        73   
      Stage III          50             40        31   
      Stage IV           8              5         4    

10.1371/journal.pone.0237811.t005

###### Prognostic factors for overall survival and event-free survival of patients with tumor stage I-IV.

![](pone.0237811.t005){#pone.0237811.t005g}

  Characteristics                                  Event-free survival   Overall Survival                                                                                                                
  ------------------------------------------------ --------------------- ------------------ -------------- ------ -------------- ------------- ------ ------------- -------------- ------ -------------- --------------
  Age                                              1.01                  1.001--1.01        **0.018**      1.01   1.003--1.013   **0.002**     1.01   1.004--1.01   **\<0.0001**   1.01   1.005--1.015   **\<0.001**
  Family history of breast and/or ovarian cancer                                                                                                                                                         
      No                                           1.00                                                    1.00                                1.00                                1.00                  
      Yes                                          0.87                  0.73--1.02         0.09           1.01   0.84--1.23     0.89          0.84   0.71--1.00    0.053          0.98   0.80--1.20     0.87
  T staging                                                                                                                                                                                              
      T1-2                                         1.00                                                    1.00                                1.00                                1.00                  
      T3-4                                         2.59                  2.30--2.91         **\<0.0001**   1.21   1.15--1.27     **\<0.001**   2.90   2.56--3.29    **\<0.0001**   1.24   1.17--1.31     **\<0.0001**
  N staging                                                                                                                                                                                              
      N0                                           1.00                                                    1.00                                1.00                                1.00                  
      N1                                           2.01                  1.74--2.31         **\<0.0001**   1.54   1.30--1.81     **\<0.001**   1.97   1.70--2.29    **\<0.0001**   1.41   1.19--1.67     **\<0.001**
      N2                                           2.55                  2.15--3.02         **\<0.0001**   1.92   1.58--2.34     **\<0.001**   2.83   2.37--3.37    **\<0.0001**   1.98   1.62--2.42     **\<0.001**
      N3                                           3.09                  2.56--3.73         **\<0.0001**   2.52   2.03--3.13     **\<0.001**   3.34   2.84--4.05    **\<0.0001**   2.49   1.99--3.11     **\<0.001**
  Histologic grade                                                                                                                                                                                       
      Grade I-II                                   1.00                                                    1.00                                1.00                                1.00                  
      Grade III                                    1.03                  0.88--1.19         0.73           0.98   0.84--1.14     0.78          1.08   0.93--1.27    0.33           0.97   0.84--1.14     0.74
  Chemotherapy                                                                                                                                                                                           
      No                                           1.00                                                    1.00                                1.00                                1.00                  
      Adjuvant                                     0.53                  0.46--0.62         **\<0.001**    0.69   0.57--0.84     **\<0.001**   0.48   0.41--0.56    **\<0.001**    0.64   0.52--0.78     **\<0.001**
      Neoadjuvant                                  1.38                  1.20--1.59         **\<0.001**    1.18   0.97--1.44     0.10          1.41   1.22--1.63    **\<0.001**    1.24   1.02--1.51     **0.031**
  Radiotherapy                                                                                                                                                                                           
      No                                           1.00                                                    1.00                                1.00                                1.00                  
      Yes                                          0.87                  0.78--0.97         **0.010**      0.87   0.76--0.99     **0.04**      0.84   0.95--0.94    **0.003**      0.84   0.72--0.96     **0.015**

HR: hazard ratio; c: crude analysis; a: adjusted analysis for age, breast and/or ovarian cancer family history, CI: confidence interval; T staging, N Staging, histological grade, chemotherapy and radiotherapy.

Characteristics and outcomes of population who received neoadjuvant chemotherapy {#sec015}
--------------------------------------------------------------------------------

There were 744 patients that received neoadjuvant chemotherapy (NAC). Most participants did not receive NAC were ≥50 years old (50.6% vs. 44.2%, p = 0.022) and were postmenopausal (57.8% vs. 50.7%, p = 0.002). Moreover, the majority of T3-4 (86% vs 33.9%, p\<0.0001), N1+ (81.3% vs. 54.9%, p\<0.0001), and AJCC Stage III (81% vs. 34%, p\<0.001) had NAC. Higher histological grades were related to NAC (84.8% vs. 78.9%, p = 0.003). Most of the patients who received NAC were treated with radiotherapy (58.9% vs 45.5%, p\<0.0001). However, local (42.3% vs 28.7%, p\<0.001), distant recurrence (71.1% vs. 41.0%), and death (74.9% vs. 50.9%) were more frequent in patients that received NAC ([S1 Table](#pone.0237811.s001){ref-type="supplementary-material"}).

Regarding the prognostic factors in the population with NAC, we controlled the following variables in the model: age, family history of breast and/or ovarian cancer, T staging, N staging, histological grade, and radiotherapy. A higher T staging (T3-4 vs T1-2, HR: 1.77; 95% CI:1.29--2.44) and N staging (N2 vs N0; HR:1.68; 95% CI:1.24--2.29; N3 vs N0; HR: 2.70; 95%CI: 1.87--3.88) were associated with worse OS. On the other hand, radiotherapy was associated with better outcomes in OS (HR:0.69; 95% CI: 0.57--0.74) ([S2 Table](#pone.0237811.s002){ref-type="supplementary-material"}).

Discussion {#sec016}
==========

The present study provides the sociodemographic, clinicopathological and survival profile of TNBC patients over 15 years in Peru. Our results show that the patients studied were mostly middle-aged women, overweight or obese, postmenopausal, or had tumor stage III at diagnosis. Moreover, a higher tumor stage worsened the EFS (local or distant) and OS rates in contrast to patients with stages I-II. The predominant prognostic factors for mortality and disease relapse in the multivariate Cox regression analysis were advanced T and N status.

Our cohort shares similar demographic, clinical, and pathological characteristics to those described in previous reports. The age at diagnosis of patients with TNBC clusters towards younger females compared to other breast cancer subtypes. According to several studies, the median age at diagnosis does not exceed 50 years \[[@pone.0237811.ref005], [@pone.0237811.ref006]\], and as expected, more than half of our cohort was under this cutoff point. Moreover, studies have identified an association between TNBC and an increased BMI. For example, Trivers *et al*. \[[@pone.0237811.ref006]\] found that TNBC patients had an almost 2-fold greater likelihood of being obese. Likewise, Mowad *et al*. \[[@pone.0237811.ref017]\] evaluated 183 patients with TNBC and found that the majority were overweight (23%) or obese (64%). However, they did not find an association between poor prognosis and OS and disease-free survival (DFS), even though the patients with an increased BMI had larger tumor sizes, higher T stages, and tumor stages. Accordingly, we found that the most predominant was the overweight group (38.1%), and a significant number of patients were obese (almost 25%).

In relation to pathological variables, 52% of our population had stage III-IV, and 72% had tumor grade III at diagnosis. These values are higher compared to other studies in different geographic scenarios. In India, Sarin *et al*. \[[@pone.0237811.ref018]\] reported that 30.1% of TNBC cases had stage III-IV at diagnosis, while in China, Li *et al*. \[[@pone.0237811.ref013]\] reported that 35% of their population had histologic grade III at diagnosis. In the United States, a population-based study found that 22% of TNBC patients presented with stage III-IV, and 75% had histologic grade III at diagnosis \[[@pone.0237811.ref019]\]. One explanation for the higher proportion of tumor stage in our cohort may be related to the unwillingness of the women to participate in breast cancer screening programs and engage in regular cancer-preventive medical checks, which has shown leads to cancer propagation and increased tumor severity at diagnosis \[[@pone.0237811.ref020]\]. A previous study in Peruvian females found that poverty is correlated with higher tumor stage at diagnosis \[[@pone.0237811.ref021]\], which supports our assumption. One previous study in a Peruvian population found similar results, with 42% being in stage III-IV and 70% with histologic grade III, demonstrating a trend to these outcomes in this population \[[@pone.0237811.ref003]\]. Moreover, 32% of the population did not undergo surgery. This is because half of our patients were diagnosed at advanced stages or progressed during the neoadjuvant chemotherapy. Hence, although there are recommendations of case by case evaluation for the surgical approach, if the disease is at stage IV or do not respond to chemotherapy, the main objective would be improving the quality of life and the survival benefit of tumor removal is still inconclusive \[[@pone.0237811.ref022], [@pone.0237811.ref023]\].

Patients with TNBC have a lower DFS and OS than those with non-TNBC \[[@pone.0237811.ref004], [@pone.0237811.ref024]\]. Previous studies have reported a DFS of 70--80% and an OS of 70--80% at five years \[[@pone.0237811.ref004], [@pone.0237811.ref010], [@pone.0237811.ref013], [@pone.0237811.ref025]--[@pone.0237811.ref027]\]. However, few authors have focused on long-term survival outcomes at seven \[[@pone.0237811.ref013], [@pone.0237811.ref028]\], eight \[[@pone.0237811.ref011]\], and 20 years \[[@pone.0237811.ref012]\]. Similar to our median eight-year follow-up, Li *et al*. \[[@pone.0237811.ref013]\] reported 62% of DFS at nine years in a cohort of 129 Chinese patients with TNBC. Moreover, Chandra *et al*. \[[@pone.0237811.ref011]\] found a significant difference between OS rates of early (90%) and locally advanced breast cancer (51%) at eight-years, despite a median follow-up of 42 months. Furthermore, Haque *et al*. \[[@pone.0237811.ref012]\] reported an OS of 86% in patients with tumor stage I and a 63% OS in stage II at 20 years, which is similar to the patients in this cohort (stage I, 85%; and stage II, 75%). In a similar cohort of 255 Latin American patients with TNBC, Vallejos *et al*. \[[@pone.0237811.ref003]\] reported an OS of 66% at five years; however, we analyzed a wider population and expanded the observation period.

Cox regression identified that tumor size, nodal status, and chemotherapy and radiotherapy are important prognostic factors for both disease recurrence and mortality. Similarly, Abdulkarim *et al*. \[[@pone.0237811.ref029]\] analyzed 768 TNBC patients and reported that at least three positive lymph nodes increased the risk of local recurrence by 9-fold and the risk of mortality by 7-fold. In a cohort study of 605 cases, Leon-Ferre *et al*. \[[@pone.0237811.ref025]\] identified that a higher N status increases the risk of invasive recurrence, while Bhatti *et al*. \[[@pone.0237811.ref010]\] reported that both tumor size and a higher N status increased the risk of local-distant relapse and mortality in a cohort of 194 women with TNBC. The worse DFS and OS in more advanced cancer stages are congruent with the heterogeneous and aggressive behavior of TNBC \[[@pone.0237811.ref012], [@pone.0237811.ref030]\]. Our results remain consistent with these previous experiences and portray the prognostic factors for EFS in Peruvian population.

In the present study, we found that radiotherapy improved the OS of the patients. Previous studies established the benefits of this treatment in survival outcomes such as locoregional recurrence and among types of surgery \[[@pone.0237811.ref029], [@pone.0237811.ref031]\]. In our analysis radiotherapy was an additional prognostic factor to reduce the risk of mortality in the TNBC population. Another favorable prognostic factor for EFS and OS was treatment with chemotherapy. Despite the lack of targeted therapy, according to international guidelines chemotherapy was essential for the treatment of these patients and proved to be a favorable prognostic marker for this type of tumor \[[@pone.0237811.ref032], [@pone.0237811.ref033]\]. However even though new chemotherapy agents such as platines, microtubule stabilizers and monoclonal antibodies have been added to this treatment, TNBC patients still have the worst prognosis across the different phenotypes of breast cancer \[[@pone.0237811.ref034], [@pone.0237811.ref035]\].

A family history of breast or ovarian cancer is a confirmed prognostic factor for breast cancer, and it has been described that patients with TNBC have a higher proportion of family members with these diagnoses \[[@pone.0237811.ref007], [@pone.0237811.ref036]\]. However, few studies have addressed the importance of this factor in the prognosis of breast cancer \[[@pone.0237811.ref037], [@pone.0237811.ref038]\]. *Song et al*. \[[@pone.0237811.ref037]\] performed a meta-analysis in which they aimed to evaluate the influence of breast cancer history in a first-degree relative and the risk of OS and breast cancer-specific survival. They identified that a positive family history is a protective factor for OS. The authors stated that possible implications in their analysis were the quality of the studies and the heterogeneous control groups studied. In contrast, we only analyzed TNBC patients and included the outcome EFS. Although a positive family history of breast or ovarian cancer in a first- or second-degree relative tended to be a protective factor in both EFS and OS outcomes, there was also a tendency towards a worse prognosis. We focused on the triple-negative subtype in contrast to the study of Song *et al*., therefore, the difference in the expression of hormonal receptors in the patients may explain these different results. Moreover, the percentage of positive family histories in our population was smaller than that of other studies \[[@pone.0237811.ref012], [@pone.0237811.ref013], [@pone.0237811.ref038], [@pone.0237811.ref039]\], which could have affected the results. Due to the underreported data of survival outcomes, a stratified analysis based on hormonal receptors would provide better understanding of the implication of this variable in the survival of breast cancer patients.

The present study has several strengths. Previous experiences used different definitions for both OS and EFS. While some authors defined it as the time from diagnosis until the event (death or recurrence) \[[@pone.0237811.ref012], [@pone.0237811.ref013], [@pone.0237811.ref026], [@pone.0237811.ref040]\], others start the follow-up from the treatment date (medical or surgery) \[[@pone.0237811.ref010], [@pone.0237811.ref029], [@pone.0237811.ref041]\]. This latter approach prevents incurring an immortal time bias in the survival analysis by avoiding the observation time of patients without therapy. In this line, we tracked the follow-up of our patients from the date of diagnosis, hence, our results also demonstrate the long-term effectiveness of the breast cancer treatment modalities in this population. Moreover, our study included a large number of Peruvian cases, providing the sociodemographic and clinicopathological profiles of these patients. On the other hand, one limitation of our study is its retrospective design. The clinical and treatment characteristics in the medical records of many patients were incomplete or were lost during follow-up and these patients were, therefore, excluded from the analysis. While there was a high proportion of patients with positive margins in the BCS group, all received re-excision and medical treatment, which could have affected the survival outcomes in this cohort. Moreover, this was a single center experience and our results should be interpreted with caution. Our results are useful for the Peruvian or South American people, but they have to be considered with caution if extrapolated to other populations.

In conclusion, the clinicodemographic and pathological features of our TNBC patients are similar to those of other populations. However, most of our patients were diagnosed in stage III, which likely explains the lower EFS and OS rates observed. The prognostic factors of survival in the present study were also similar to those described in previous studies. The most important prognostic factor identified was the lymph node stage. New specific molecular biomarkers able to predict response to chemotherapy are needed for new therapies in patients with TNBC.
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